Vincent van der Noort

4.8k total citations · 1 hit paper
133 papers, 2.5k citations indexed

About

Vincent van der Noort is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Vincent van der Noort has authored 133 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 77 papers in Pulmonary and Respiratory Medicine, 62 papers in Oncology and 30 papers in Cancer Research. Recurrent topics in Vincent van der Noort's work include Lung Cancer Treatments and Mutations (30 papers), Cancer Immunotherapy and Biomarkers (16 papers) and Lung Cancer Research Studies (15 papers). Vincent van der Noort is often cited by papers focused on Lung Cancer Treatments and Mutations (30 papers), Cancer Immunotherapy and Biomarkers (16 papers) and Lung Cancer Research Studies (15 papers). Vincent van der Noort collaborates with scholars based in Netherlands, United States and Switzerland. Vincent van der Noort's co-authors include Paul Baas, Kim Monkhorst, Ferry Lalezari, Jeltje F. de Vries, Willemijn S.M.E. Theelen, Joachim G.J.V. Aerts, Idris Bahce, Adrianus J. de Langen, Daphne W. Dumoulin and Heike Peulen and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

In The Last Decade

Vincent van der Noort

120 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non–Small Cell Lung Cancer

2019 651 citations Willemijn S.M.E. Theelen, Ferry Lalezari et al. JAMA Oncology profile →

Peers

Countries citing papers authored by Vincent van der Noort

Since Specialization

Citations

This map shows the geographic impact of Vincent van der Noort's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vincent van der Noort with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vincent van der Noort more than expected).

Fields of papers citing papers by Vincent van der Noort

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vincent van der Noort. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vincent van der Noort. The network helps show where Vincent van der Noort may publish in the future.

Co-authorship network of co-authors of Vincent van der Noort

This figure shows the co-authorship network connecting the top 25 collaborators of Vincent van der Noort. A scholar is included among the top collaborators of Vincent van der Noort based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vincent van der Noort. Vincent van der Noort is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Overall Survival With First-Line vs Second-Line CDK4/6 Inhibitor Use in Advanced Breast Cancer 2026 ·JAMA Oncology ·(unknown), (unknown), (unknown), Vincent van der Noort, E. van den Pol, (unknown), Sandra D. Bakker, Sjoerd Hovenga, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Saskia M. Wilting, (unknown), (unknown), (unknown)	0
2	2096MO Systemic therapy, gastrectomy and CRS/HIPEC vs systemic therapy alone for gastric cancer with limited peritoneal dissemination: Results of the randomised PERISCOPE II trial 2025 ·Annals of Oncology ·(unknown), (unknown), Vincent van der Noort, Valesca P. Retèl, (unknown), Irene E.G. van Hellemond, Bas P. L. Wijnhoven, Bianca Mostert, Richard van Hillegersberg, Nadia Haj Mohammad, Boudewijn van Etten, (unknown), Olli Helminen, Jakob Hedberg, Paul Cashin, Daniel Willy Kjær, Liudmila L. Kodach, Marieke A. Vollebergh, Johanna van Sandick	0
3	The feasibility of using real world data as external control arms in oncology trials 2025 ·Drug Discovery Today ·(unknown), (unknown), Vincent van der Noort, Toine C. G. Egberts, J. H. Beijnen, Alwin D. R. Huitema	1
4	Health economic outcomes and costs of CDK4/6 inhibitor use in first- versus second-line for advanced breast cancer: A cost-effectiveness analysis of the phase 3 SONIA trial 2025 ·European Journal of Cancer ·(unknown), (unknown), Inge R. Konings, (unknown), Vincent van der Noort, E. van den Pol, (unknown), (unknown), F. Van den Berkmortel, Helga Droogendijk, Danny Houtsma, Hendrika M. Oosterkamp, (unknown), Ester Siemerink, Jolien Tol, Annette A. van Zweeden, A. Elise van Leeuwen‐Stok, Gabe S. Sonke, Agnes Jager, Hedwig M. Blommestein	1
5	1258MO Low dose versus standard dose pembrolizumab for treatment of stage IV stage non-small cell lung carcinoma: Results of the pre-planned interim analysis of the NVALT-30 clinical trial 2024 ·Annals of Oncology ·(unknown), Vincent van der Noort, Rob ter Heine	6
6	Omission of axillary lymph node dissection in cN2-3 breast cancer patients with an excellent response on primary systemic treatment is safe: 4-year oncologic outcome of the MARI protocol 2024 ·European Journal of Cancer ·(unknown), (unknown), (unknown), Marcel P. M. Stokkel, Ewout J. N. Groen, Claudette E. Loo, Vincent van der Noort, Gabe S. Sonke, N.S. Russell, Frederieke van Duijnhoven, (unknown)	1
7	352P Cost-effectiveness of CDK4/6 inhibitors in first- vs second-line for advanced breast cancer (ABC) in the phase III SONIA trial (BOOG 2017-03) 2024 ·Annals of Oncology ·(unknown), Stephen B. H. Kent, Inge R. Konings, (unknown), Vincent van der Noort, E. van den Pol, (unknown), (unknown), (unknown), Frans Erdkamp, Danny Houtsma, Hendrika M. Oosterkamp, (unknown), (unknown), J. Tol, Annette A. van Zweeden, A. Elise van Leeuwen‐Stok, Gabe S. Sonke, Agnes Jager, Hedwig M. Blommestein	1
8	Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non–Small Cell Lung Cancer—Results from the Drug Rediscovery Protocol 2024 ·Clinical Cancer Research ·(unknown), (unknown), Laurien J. Zeverijn, Birgit S. Geurts, (unknown), Gijs F. de Wit, Paul Roepman, Anne M.L. Jansen, Vincent van der Noort, Egbert F. Smit, Ann Hoeben, Lizza Hendriks, Michel M. van den Heuvel, Berber Piet, Gerarda J.M. Herder, Sayed M.S. Hashemi, Hans Gelderblom, Henk M.W. Verheul, Emile E. Voest, Adrianus J. de Langen	1
9	Maximizing Treatment Opportunities: Assessing Protocol Waivers’ Impact on Safety and Outcome in the Drug Rediscovery Protocol 2024 ·Clinical Cancer Research ·Jade M. van Berge Henegouwen, Laurien J. Zeverijn, Birgit S. Geurts, Louisa R. Hoes, Hanneke van der Wijngaart, Vincent van der Noort, Alwin D. R. Huitema, Filip De Vos, Katrien Grünberg, Haiko J. Bloemendal, Henk M.W. Verheul, Emile E. Voest, Hans Gelderblom	1
10	Head-to-head comparison of composite and individual biomarkers to predict clinical benefit to PD-1 blockade in non-small cell lung cancer 2024 ·PLoS ONE ·Karlijn Hummelink, Vincent van der Noort, Mirte Muller, Robert D. Schouten, Michel M. van den Heuvel, Daniela S. Thommen, Egbert F. Smit, Gerrit A. Meijer, Kim Monkhorst	2
11	Optimising primary molecular profiling in non-small cell lung cancer 2024 ·PLoS ONE ·Robert D. Schouten, (unknown), (unknown), Vincent van der Noort, Ronald Damhuis, Erik H.F.M. van der Heijden, (unknown), Nicole P. Barlo, Anne S. R. van Lindert, (unknown), (unknown), Annet Smit, (unknown), B. Maat, Ed Schuuring, Hans Blaauwgeers, Stefan M. Willems, Kim Monkhorst, Daan van den Broek, Michel M. van den Heuvel	1
12	Combined Cabazitaxel and Carboplatin Treatment of Metastatic Castration Resistant Prostate Cancer Patients, With Innate or Acquired Resistance to Cabazitaxel Monotherapy 2024 ·Clinical Genitourinary Cancer ·Kim van der Zande, (unknown), Paul Hamberg, (unknown), (unknown), (unknown), Annegien Broeks, Sten Cornelissen, Aart Beeker, Vincent van der Noort, Wilbert Zwart, Andries M. Bergman	2
13	Histopathological Concordance between Prostate Biopsies and Radical Prostatectomy Specimens – Implications of Transrectal and Transperineal Biopsy Approaches 2023 ·European Urology Open Science ·(unknown), (unknown), (unknown), (unknown), Kurdo Barwari, (unknown), (unknown), A.M.E. Claessen, (unknown), Vincent van der Noort, Martijn Smeenge, Ton A. Roeleveld, (unknown), (unknown), (unknown), André N. Vis, Elise M. Bekers, Pim J. van Leeuwen, Henk G. van der Poel	1
14	1392P Safety and efficacy of crizotinib in MET mutated (METmut) advanced non-small cell lung Cancer (aNSCLC): Results from the Drug Rediscovery Protocol (DRUP) 2023 ·Annals of Oncology ·Karin Verkerk, (unknown), Laurien J. Zeverijn, Birgit S. Geurts, (unknown), (unknown), Paul Roepman, Anne M.L. Jansen, Vincent van der Noort, Egbert F. Smit, Ann Hoeben, Lizza Hendriks, Carla M.L. van Herpen, Berber Piet, (unknown), Sayed M.S. Hashemi, Hans Gelderblom, Henk M.W. Verheul, Emile E. Voest, J. De Langen	3
15	Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target HER2 Bypass Track Resistance in EGFR Mutation-Positive NSCLC 2023 ·JTO Clinical and Research Reports ·(unknown), Adrianus J. de Langen, Kim Monkhorst, Mirjam C. Boelens, Daan van den Broek, Vincent van der Noort, Cornedine J. de Gooijer, (unknown), Anthonie J. van der Wekken, Lizza Hendriks, Sayed M.S. Hashemi, Marthe S. Paats, Anne‐Marie C. Dingemans, Egbert F. Smit	19
16	PD-1T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC 2022 ·Clinical Cancer Research ·Karlijn Hummelink, Vincent van der Noort, Mirte Muller, Robert D. Schouten, Ferry Lalezari, Dennis Peters, Willemijn S.M.E. Theelen, Viktor H. Koelzer, Kirsten D. Mertz, Alfred Zippelius, Michel M. van den Heuvel, Annegien Broeks, John B.A.G. Haanen, Ton N. Schumacher, Gerrit A. Meijer, Egbert F. Smit, Kim Monkhorst, Daniela S. Thommen	26
17	The oncological characteristics of non‐prostate‐specific membrane antigen (PSMA)‐expressing primary prostate cancer on preoperative PSMA positron emission tomography/computed tomography 2022 ·British Journal of Urology ·(unknown), Maarten L. Donswijk, Elise M. Bekers, Yves J. L. Bodar, Dennie Meijer, R. Jeroen A. van Moorselaar, Daniela E. Oprea‐Lager, Vincent van der Noort, Pim J. van Leeuwen, André N. Vis, Henk G. van der Poel	6
18	Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer 2022 ·European Journal of Cancer ·Jade M. van Berge Henegouwen, (unknown), Louisa R. Hoes, Hanneke van der Wijngaart, Laurien J. Zeverijn, Daphne van der Velden, Paul Roepman, Wendy W.J. de Leng, Anne M.L. Jansen, Erik van Werkhoven, Vincent van der Noort, Anthonie J. van der Wekken, Adrianus J. de Langen, Emile E. Voest, Henk M.W. Verheul, Egbert F. Smit, Hans Gelderblom	16
19	Is pneumonectomy justifiable for patients with a locoregional recurrence or persistent disease after curative intent chemoradiotherapy for locally advanced non-small cell lung cancer? 2020 ·Lung Cancer ·(unknown), Chris Dickhoff, Vincent van der Noort, Houke M. Klomp, (unknown), Max Dahele, Idris Bahce, Alexander A. F. A. Veenhof, Egbert F. Smit, Koen J. Hartemink	3
20	PI3K pathway protein analyses in metastatic breast cancer patients receiving standard everolimus and exemestane 2020 ·Journal of Cancer Research and Clinical Oncology ·(unknown), Mark Opdam, Vincent van der Noort, Joyce Sanders, (unknown), (unknown), Karin Beelen, Sabine C. Linn, Epie Boven	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact